Core Insights - The Chemours Company (CC) has updated its second-quarter 2025 outlook, expecting consolidated net sales to be at the high end of the original range with a sequential mid-teens increase [1] Segment Performance - The Thermal & Specialized Solutions (TSS) segment anticipates a sequential net sales increase of around 25% due to stronger demand for Opteon Refrigerants, with an expected sequential adjusted EBITDA increase of roughly 40% [2] - In contrast, the Titanium Technologies (TT) segment projects a 15% sequential decline in adjusted EBITDA, attributed to operational disruptions at its U.S. site, resulting in approximately $15 million in incremental costs and other one-time operational disruptions costing around $10 million [3] - The Advanced Performance Materials (APM) segment's net sales are predicted to align with low teens sequential growth expectations, while adjusted EBITDA is expected to increase around 25% sequentially due to stronger overall cost performance [4] Financial Expectations - CC's consolidated adjusted EBITDA is now expected to be in the range of $215 million to $225 million, with positive consolidated free cash flow projected for the second quarter [5][9] - The company has experienced a significant stock decline of 51.5% over the past year, compared to the industry's 24.7% decline [7]

Toronto, Ontario--(Newsfile Corp. - Le 2 juin/June 2025) - Core Assets Corp. has announced a name change to Core Silver Corp. and a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every ten (10) pre-consolidated common shares. As a result, the outstanding shares of the company will be reduced to approximately 12,710,565 common shares. The shares will begin trading on a consolidated basis and with a new name and CUSIP number on June 4, ...

Core Viewpoint - Chemours Company has partnered with DataVolt to develop innovative liquid cooling solutions for data centers, aiming to enhance efficiency and sustainability in response to the growing demand for AI and next-generation chips [1][2][4]. Group 1: Partnership and Technology Development - The collaboration will focus on two-phase direct-to-chip and immersion cooling technologies, leveraging Chemours' ultra-low global warming potential Opteon dielectric fluids [3]. - This partnership aims to accelerate the adoption of liquid cooling technologies, reducing the total cost of ownership and environmental impact while improving performance and efficiency [2][4]. Group 2: Market Context and Financial Outlook - Chemours' shares have decreased by 59.7% over the past year, compared to a 27.2% decline in the industry [5]. - The company anticipates a sequential increase in consolidated net sales in the low to mid-teens for the second quarter, with adjusted EBITDA expected to rise by 40% to 45% [6]. - For the full year 2025, adjusted EBITDA is projected to be between $825 million and $950 million, with capital expenditures estimated at $225 million to $275 million [6].

Core Viewpoint - The Chemours Company reported a net loss of $4 million for Q1 2025, a significant decline from a net income of $54 million in the same quarter last year, indicating challenges in profitability despite a slight increase in net sales [1]. Financial Performance - The company achieved first-quarter net sales of $1,368 million, reflecting a 1.3% increase year-over-year and surpassing the Zacks Consensus Estimate of $1,355.2 million, driven by a 5% increase in volume despite a 4% drop in pricing and a 1% negative currency impact [2]. - Adjusted EBITDA for the quarter declined by 13% year-over-year to $166 million, primarily due to lower pricing across business segments, particularly in Thermal & Specialized Solutions and Titanium Technologies [3]. Segment Highlights - The Titanium Technologies division reported revenues of $597 million, a 1% increase from the previous year, exceeding the estimate of $579.2 million, attributed to a 6% increase in volumes, offset by a 4% decrease in price [3]. - The Thermal & Specialized Solutions segment saw revenues of $466 million, a 3% year-over-year increase, but fell short of the estimate of $479.2 million, with net sales growth driven by a 10% increase in volume, slightly offset by a 6% price decline [4]. - Revenues in the Advanced Performance Materials unit amounted to $294 million, a decline of approximately 3% year-over-year, yet beating the estimate of $289.4 million, with a 1% drop in volume and a 2% currency headwind [5]. Cash Flow and Capital Expenditures - Cash used by operating activities in Q1 2025 was $112 million, down from $290 million in the prior-year quarter, while capital expenditures were $84 million compared to $102 million in the previous year [6]. - The company reduced its dividend by 65% to $0.0875 per share to align with its capital allocation strategy [6]. Outlook - The company anticipates consolidated net sales to increase in the low to mid-teens sequentially in Q2, with adjusted EBITDA expected to rise by 40% to 45% [7]. - Full-year 2025 adjusted EBITDA is projected to be between $825 million and $950 million, with capital expenditures expected to range from $225 million to $275 million [7]. Stock Performance - Chemours shares have declined by 61.4% over the past year, compared to a 28.3% decline in the industry [8].

Financial Data and Key Metrics Changes - Consolidated net sales for Q1 2025 were approximately $1.4 billion, consistent with the prior year, with a 5% increase in volume offset by a 4% price decline and a slight 1% currency headwind [19] - Adjusted EBITDA for Q1 2025 was $166 million, down from $191 million in the prior year, primarily due to lower pricing across all businesses and unfavorable currency movements [19][20] - The company reported a net loss of $4 million or $0.03 per diluted share compared to net income of $54 million or $0.36 per diluted share in the prior year [19][20] Business Segment Performance - TSS achieved net sales of $466 million in Q1 2025, a 3% increase from the prior year, driven by a 10% volume increase, partially offset by a 6% price decline [21][22] - TT's net sales increased 1% year over year to $597 million, primarily due to a 6% increase in volume, offset by a 4% decrease in price [25] - APM reported net sales of $294 million, a 3% decrease compared to the prior year, driven by a 2% currency headwind and a 1% decrease in volume [27] Market Data and Key Metrics Changes - In TSS, Opteon refrigerants saw a 40% year-over-year net sales increase due to increased demand related to the U.S. AIM Act [6][22] - TT's sales in Western markets, which have established fair trade regulations, drove a 12% sales increase sequentially [11] - Weaker sales were noted in China, India, and other parts of Asia and Latin America due to Chinese TiO2 product dumping [12] Company Strategy and Industry Competition - The company announced a strategic agreement with Naveen Fluorine to produce Opteon two-phase immersion cooling fluid, addressing data cooling needs driven by AI and next-generation chips [5] - The Pathway to Thrive strategy focuses on enabling growth and operational excellence, with a commitment to cost reductions and portfolio management [46][55] - The company anticipates a shift towards low GWP offerings, with Freon sales projected to decrease by half in 2025 compared to the prior year [36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in mitigating impacts from recent tariff announcements and emphasized the importance of maintaining a flexible balance sheet [16][41] - The company expects strong results for TSS in 2025, with continued double-digit net sales growth in Opteon refrigerants [36] - APM is expected to face ongoing weakness in cyclical end markets, but cost reduction efforts are anticipated to alleviate some headwinds [40] Other Important Information - The company announced a 65% reduction in its dividend to $0.08 per share to enhance balance sheet flexibility [34][68] - Consolidated gross debt stood at $4.1 billion with approximately $1.1 billion in total liquidity as of March 31, 2025 [30] - The company is focused on resolving legacy liabilities and improving operational performance as part of its long-term strategy [54][55] Q&A Session Summary Question: Capacity from Naveen Fluorine and commercialization timeline - Management highlighted a $14 million investment in the asset, with field trials expected to require two to five tons, and opportunities for additional volume as customer commitments are secured [60] Question: TiO2 EBITDA expectations for 2025 - Management confirmed that 2025 EBITDA is expected to be better than 2024, with a focus on optimizing cash conversion related to high-grade ore contracts [62][64] Question: Timing of dividend cut - The dividend reduction was made to provide balance sheet flexibility for growth investments and to settle liabilities responsibly [68] Question: TiO2 pricing trends in regulated markets - Management noted stabilization in pricing and volume increases in fair trade markets, but refrained from discussing forward pricing [73] Question: Supply tightness in refrigerants and cylinders - Management indicated that the cylinder shortage is not a Chemours issue and expects normalization in the next couple of months [83]

Financial Data and Key Metrics Changes - The consolidated net sales for Q1 2025 were approximately $1.4 billion, consistent with the prior year, with a 5% increase in volume offset by a 4% price decline and a slight 1% currency headwind [20] - Adjusted EBITDA for Q1 2025 was $166 million, down from $191 million in the prior year, primarily due to lower pricing across all businesses and unfavorable currency movements [20][21] - The company reported a net loss of $4 million or $0.03 per diluted share compared to net income of $54 million or $0.36 per diluted share in the prior year [20][21] Business Segment Performance - TSS achieved net sales of $466 million, a 3% increase from the prior year, driven by a 10% volume increase, partially offset by a 6% price decline [21][22] - TT's net sales increased 1% year over year to $597 million, primarily due to a 6% increase in volume, offset by a 4% decrease in price [26] - APM reported net sales of $294 million, a 3% decrease compared to the prior year, driven by a 2% currency headwind and a 1% decrease in volume [28] Market Data and Key Metrics Changes - In TSS, Opteon refrigerants saw a 40% year-over-year net sales increase due to increased demand related to the U.S. AIM Act [6][22] - The TiO2 market in North America, Europe, and Brazil, categorized as western markets, drove a 12% sales increase sequentially, reflecting the highest first-quarter combined regional sales since 2022 [12][13] - Weaker sales were noted in China, India, and other parts of Asia and Latin America due to high levels of Chinese TiO2 product being dumped [12][13] Company Strategy and Industry Competition - The company announced a strategic agreement with Naveen Fluorine to produce Opteon two-phase immersion cooling fluid, addressing data cooling center needs created by AI and next-generation chips [5][6] - Chemours is focused on executing its "Pathway to Thrive" strategy, which includes driving growth in low GWP offerings and managing costs effectively [5][46] - The company anticipates a shift in its product mix towards Opteon refrigerants, projecting a 50% decrease in Freon sales in 2025 compared to the prior year [36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in mitigating the impact of recent tariff announcements and emphasized the company's strong competitive position across key markets [17][18] - The company expects Q2 2025 net sales to increase in the low to mid-teens sequentially, with adjusted EBITDA anticipated to increase between 40% to 45% sequentially [39] - For the full year 2025, adjusted EBITDA is expected to be in the range of $825 million to $950 million, reflecting a refined outlook based on market dynamics [40][41] Other Important Information - The company announced a 65% reduction in its dividend to $0.08 per share, aligning with its capital allocation strategy to maintain balance sheet flexibility [34][67] - As of March 31, 2025, consolidated gross debt stood at $4.1 billion, with approximately $1.1 billion in total liquidity [31] - The company is focused on resolving legacy liabilities and has engaged with policymakers to advocate for its essential chemistry amid evolving regulatory landscapes [51][52] Q&A Session Summary Question: Can you help us think about the capacity provided by Naveen Fluorine and the timeline for commercialization? - The company is investing about $14 million in the asset, with field trials expected to require two to five tons, and anticipates customer commitments after these trials [57][59] Question: Are you expecting 2025 EBITDA to be up versus 2024? - Yes, 2025 is expected to be better than 2024 in terms of earnings, particularly in the TT segment [61][64] Question: Why now for the dividend cut, and why not eliminate it completely? - The resizing of the dividend allows for balance sheet flexibility to execute on growth investments and settle liabilities responsibly [67] Question: How have TiO2 prices been trending in regulated markets? - There is stabilization in price and volume increases in fair trade markets, with expectations for continued strength [72][73] Question: What is the outlook for supply tightness in refrigerants and cylinders? - The company is addressing cylinder shortages through additional shifts and third-party operations, expecting normalization in the next couple of months [83][84]

Industry Overview - The chemicals industry has faced significant challenges over the past year, including weak industrial demand, a slowdown in China, and chronic excess supply [1] - These factors have resulted in weak pricing and slow volumes within the industry [1] Company Specifics - Chemours (NYSE: CC) is mentioned as being affected by the overall industry conditions, although specific performance metrics for Chemours are not detailed in the provided text [1]

For the quarter ended March 2025, Chemours (CC) reported revenue of $1.37 billion, up 1.3% over the same period last year. EPS came in at $0.13, compared to $0.32 in the year-ago quarter.The reported revenue represents a surprise of +0.94% over the Zacks Consensus Estimate of $1.36 billion. With the consensus EPS estimate being $0.19, the EPS surprise was -31.58%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectatio ...

Group 1: Earnings Performance - Chemours reported quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.19 per share, and down from $0.32 per share a year ago, representing an earnings surprise of -31.58% [1] - The company posted revenues of $1.37 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.94%, compared to year-ago revenues of $1.35 billion [2] - Over the last four quarters, Chemours has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - Chemours shares have lost about 28.4% since the beginning of the year, while the S&P 500 has declined by -3.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.57 on $1.59 billion in revenues, and $1.81 on $5.89 billion in revenues for the current fiscal year [7] Group 3: Industry Context - The Zacks Industry Rank indicates that the Chemical - Diversified sector is currently in the bottom 18% of over 250 Zacks industries, suggesting potential challenges for stocks in this category [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The current estimate revisions trend for Chemours is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]

Financial Performance - Net Sales reached $1368 million in 1Q25, a slight increase of $6 million compared to 1Q24[7] - Adjusted EBITDA was $166 million in 1Q25, a decrease of $25 million compared to $191 million in 1Q24[7] - The company experienced a Net Loss of $4 million in 1Q25, compared to a Net Income of $54 million in 1Q24[7] - Free Cash Flow was negative $196 million in 1Q25, compared to negative $392 million in 1Q24[7] - The company returned $37 million in cash to shareholders in Q1 2025[6] Segment Performance - TSS (Thermal & Specialized Solutions) Net Sales were $466 million in 1Q25, with Adjusted EBITDA at $141 million[15] - TT (Titanium Technologies) Net Sales were $597 million in 1Q25, with Adjusted EBITDA at $50 million[15] - APM (Advanced Performance Materials) Net Sales were $294 million in 1Q25, with Adjusted EBITDA at $32 million[15] - Opteon Refrigerants experienced a 40% YoY Net Sales growth in TSS[6] Strategic Initiatives and Outlook - The company is executing its "Pathway to Thrive" three-year corporate strategy[6] - The company anticipates a low-to-mid teens percentage increase in Net Sales and a 40% to 45% sequential increase in Adjusted EBITDA for 2Q25[49, 51] - The company expects Adjusted EBITDA for full year 2025 to be in the range of $825 million to $950 million[54] - The company is expanding into the liquid cooling market, projecting a $3 billion addressable market by 2030[41]